Treatment resistance after sequential interruption of a non-nucleoside reverse transcriptase inhibitor-based repimen

被引：4
|
作者：
Dargere, Sylvie [1 ]
Parienti, Jean-Jacques [1 ]
Verdon, Renaud [1 ]
机构：
[1] Cote Nacre Univ Hosp, Dept Med, Infect Dis Unit, Caen, France
来源：
AIDS | 2007年 / 21卷 / 07期
关键词：
D O I：
10.1097/QAD.0b013e3280b077b6
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：879 / 880
页数：2
相关论文
共 50 条
  • [1] Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen
    Fox, Zoe
    Phillips, Andrew
    Cohen, Cal
    Neuhaus, Jacquie
    Baxter, John
    Emery, Sean
    Hirschel, Bernard
    Hullsiek, Kathy Huppler
    Stephan, Christoph
    Lundgren, Jens
    [J]. AIDS, 2008, 22 (17) : 2279 - 2289
  • [2] Adherence and persistence with non-nucleoside reverse transcriptase inhibitor-based antiretroviral regimens
    Taneja, Charu
    Juday, Timothy
    Gertzog, Larry
    Edelsberg, John
    Correll, Todd
    Hebden, Tony
    Oster, Gerry
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (15) : 2111 - 2118
  • [3] Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies
    Anta, Lourdes
    Llibre, Josep M.
    Poveda, Eva
    Blanco, Jose L.
    Alvarez, Marta
    Perez-Elias, Maria J.
    Aguilera, Antonio
    Caballero, Estrella
    Soriano, Vicente
    de Mendoza, Carmen
    [J]. AIDS, 2013, 27 (01) : 81 - 85
  • [4] Effectiveness and durability of non-nucleoside reverse transcriptase inhibitor-based therapy in HIV clinical practice
    Kan, Virginia L.
    [J]. AIDS, 2007, 21 (07) : 880 - 882
  • [5] HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen
    Sungkanuparph, Somnuek
    Kiertiburanakul, Sasisopin
    Apisarnthanarak, Anucha
    Malathum, Kumthorn
    Sathapatayavongs, Boonmee
    [J]. INTERNATIONAL JOURNAL OF STD & AIDS, 2007, 18 (12) : 832 - 834
  • [6] Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone
    Waters, Laura
    Bansi, Loveleen
    Asboe, David
    Pozniak, Anton
    Smit, Erasmus
    Orkin, Chloe
    Fearnhill, Esther
    Dunn, David
    Phillips, Andrew
    [J]. ANTIVIRAL THERAPY, 2013, 18 (02) : 213 - 219
  • [7] Rapid CD4 decline after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in a resource-limited setting
    Sungkanuparph S.
    Kiertiburanakul S.
    Apisarnthanarak A.
    Malathum K.
    Watcharananan S.
    Sathapatayavongs B.
    [J]. AIDS Research and Therapy, 4 (1)
  • [8] Discontinuation of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy due to nucleoside analogue reverse transcriptase inhibitorrelated metabolic toxicity
    Haddow, L. J.
    Wood, C. W.
    Ainsworth, J. G.
    [J]. INTERNATIONAL JOURNAL OF STD & AIDS, 2007, 18 (05) : 343 - 346
  • [9] Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection
    Ripamonti, Diego
    Maggiolo, Franco
    [J]. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2008, 9 (08) : 899 - 912
  • [10] Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor
    Sharma, Mamta
    Saravolatz, Louis D.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (02) : 250 - 256
12345